doi: 10.1136/bmj.c869 Summary Keywords obesity, GLP-1, GLP-1 receptor analog, exenatide, pediatrics, glycemic control, GLP-1 receptor agonist, treatment Citation Stenlid R, Cerenius SY, Wen Q, Aydin BK, Manell H, Chowdhury A, Kristinsson H, Ciba I, Gjessing ES, Mrwald K, Gomahr J, Heu V, Weghuber D, Forslund A and Bergsten P (2023) Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
Availability in India and Mumbai depends on regulatory approval and trials
Some of these companies are large international contract manufacturers with advanced research facilities, while others are specialized laboratories known for their flexibility and innovation in skincare formulation
When to Contact Your PlexusDx Provider About Sweating Most sweating related to GLP-1 therapy is mild and self-limiting, but you should reach out if you experience drenching night sweats that soak through clothing and bedding, sweating accompanied by fever or chills, or sweating that develops suddenly after weeks of stable treatment
